Existing anti-angiogenic therapeutic strategies for patients with metastatic colorectal cancer progressing following first-line bevacizumab-based therapy


Kanat O., Ertas H.

WORLD JOURNAL OF CLINICAL ONCOLOGY, vol.10, no.2, pp.52-61, 2019 (Journal Indexed in ESCI) identifier identifier

  • Publication Type: Article / Review
  • Volume: 10 Issue: 2
  • Publication Date: 2019
  • Doi Number: 10.5306/wjco.v10.i2.52
  • Title of Journal : WORLD JOURNAL OF CLINICAL ONCOLOGY
  • Page Numbers: pp.52-61

Abstract

Continuous inhibition of angiogenesis beyond progression is an emerging treatment concept in the management of metastatic colorectal cancer patients with prior bevacizumab exposure. Treatment options include the continuation or reintroduction of bevacizumab during the second-line chemotherapy or switching to a different antiangiogenic monoclonal antibody such as aflibercept or ramucirumab. In the selection of treatment, patient-based factors such as performance status, age, tumor burden, and tolerance and sensitivity to the firstline bevacizumab-based therapy, as well as treatment-related factors such as toxicity, efficacy, and cost, should be taken into consideration.